LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $94.63.

Several research analysts recently issued reports on LMAT shares. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock.

LeMaitre Vascular Stock Up 1.7 %

Shares of NASDAQ LMAT opened at $98.65 on Tuesday. The firm has a market cap of $2.22 billion, a PE ratio of 53.91, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a twelve month low of $59.87 and a twelve month high of $109.58. The business has a fifty day simple moving average of $95.97 and a two-hundred day simple moving average of $93.74.

Institutional Trading of LeMaitre Vascular

Several institutional investors and hedge funds have recently made changes to their positions in the company. Townsquare Capital LLC raised its stake in LeMaitre Vascular by 38.0% during the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after acquiring an additional 13,210 shares during the last quarter. Barclays PLC increased its position in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares during the period. Charles Schwab Investment Management Inc. increased its position in LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after purchasing an additional 11,395 shares during the period. Creative Planning grew its holdings in shares of LeMaitre Vascular by 20.7% in the 3rd quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after acquiring an additional 617 shares during the period. Finally, Copeland Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after acquiring an additional 11,318 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.